Posted in Friday Collection on January 26, 2008 | 1 Comment »
In a shocking new development which has organic farmers rejoicing nationwide, Behemoth Pharmaceuticals President J.P. MacRost announced this week that his company is releasing new “free-range” Vytorin to deal with both sources of Vytorin angst - pharma and phraud.
“We’ve been secretly working on our all-natural, free-range version for quite some time, “stated MacRost at a [...]
Posted in Abbott, Marketing, Pharma, Pharmaceutical, Web, tagged Abbott labs on January 26, 2008 | No Comments »
In my occasional series on how effectively pharma companies present themselves on their website home pages, today we arrive at Abbott labs (Abbott.com).
I will admit right off that I’ve never been a fan of the Abbott logo. I find it singularly uninspiring and I wish that a company that has so much going for it [...]
Posted in No Bad Training, Sales training, Training, tagged Needs assessment on January 26, 2008 | 1 Comment »
Short answer - you do.
How many times have you been ambushed with this scenario: “We need a new workshop on so-and-so for the March POA meeting!” or, “We need a new training piece on such-and-such competitor!” or, “We need to jazz up Day 1 of New Hire Training!”
Now, maybe you do need something along those [...]
Posted in Friday Collection on January 26, 2008 | No Comments »
Who doesn’t like to save money? Here’s a page with 21 money-savings sites around the web.
Create your own, instant, no-cost, ad-hoc chat room on-line (ChatMaker).
Fun with time-lapse photography. 13 very cool time-lapse wonders. It’s hard to pick a favorite, though the Milky Way clip is really astonishing. This is a 3/4 cup of coffee stop [...]
Posted in SPBT, tagged chip heath, made to stick, storytelling on January 26, 2008 | No Comments »
I notice that Chip Heath has been invited to give the keynote at the upcoming SPBT conference. Superb choice! I’ve been corresponding with Chip and Dan since they released their very helpful book Made to Stick (reviewed previously on this blog), and this should be a not-to-be-missed session.
One of their main points in making your [...]
Posted in Pharma, Pharmaceutical, Training on January 26, 2008 | No Comments »
Here’s a helpful link to a number of job openings in pharma and training. You can play with the search criteria and look at whatever slices you need.
Posted in Daiichi Sankyo, Medical Devices, Medicine, Merck, News, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Roche, Schering, Wyeth, tagged Lipitor, stent, ventana on January 26, 2008 | No Comments »
Daiichi-Sankyo’s Welchol gets approval for improving glycemic control in adults with Type 2 diabetes.
Novartis - for 11 years in a row - grabs the top spot in the Verispan Managed Care audit.
Roche prevails in its takeover bid for Ventana.
The knives are still out - Wyeth to cut another 10% of workforce?
Vytoringate - Merck and Schering-Plough, [...]
Posted in Healthcare, Medicine, Pharmaceutical, Sales on January 24, 2008 | 2 Comments »
Medical Marketing and Media is reporting that nearly 1 in 5 doctors are not seeing drug/device reps, and about the same percentage are requiring appointments.
Here’s an excerpt from the article (click the link above for the full story):
Nineteen percent of US office-based physicians refuse to see drug and device industry sales reps, according to a [...]
Posted in Marketing, Pharma, Pharmaceutical, Technology, tagged emarketing, epharma on January 22, 2008 | 1 Comment »
IIRUSA puts on the ePharma Summit each year (this is the 7th annual), and it’ll be in Philadelphia Jan. 28-30. Lots of great speakers and leading-edge topics.
As always, I’ll be keeping my eyes out for innovative approaches and technology solutions.
All the info and registration links are here. Hope to see you there!
Posted in No Bad Training, Sales training, Training on January 21, 2008 | No Comments »
In virtually all areas of human endeavor, it’s simply easier to go with the crowd.
Why do pharma companies target thought leaders? Simple - most of us are followers. Since we don’t all have the time, expertise, or clout to forge new paths, the safest route is typically to do what everyone else is doing.
And that’s [...]
